Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study
Authors:
- Johannes F.E. MannJMJohannes F.E. Mann
- Hertzel C. GersteinHGHertzel C. Gerstein
- Qi-Long YiQYQi-Long Yi
- Jörg FrankeJFJörg Franke
- Eva M. LonnELEva M. Lonn
- Byron J. HoogwerfBHByron J. Hoogwerf
- Andrew RashkowARAndrew Rashkow
- Salim YusufSYSalim Yusuf
- 1 November 2003
- journal article
- clinical trial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 42 (5) , 936-942
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2003
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized TrialAnnals of Internal Medicine, 2001
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudyThe Lancet, 2000
- Nephropathy in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 1999
- Long-term Renoprotective Effect of Angiotensin-converting Enzyme Inhibition in Non—insulin-dependent Diabetes MellitusArchives of internal medicine (1960), 1996
- Prevention of diabetic renal disease with special reference to microalbuminuriaThe Lancet, 1995
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993